NYSE:NUVB - New York Stock Exchange, Inc. - US67080N1019 - Common Stock - Currency: USD
2.25
+0.22 (+10.84%)
The current stock price of NUVB is 2.25 USD. In the past month the price increased by 5.63%. In the past year, price decreased by -26.95%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 51.98 | 678.00B | ||
JNJ | JOHNSON & JOHNSON | 15.19 | 367.19B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.48 | 302.61B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.54 | 222.20B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.8 | 216.87B | ||
MRK | MERCK & CO. INC. | 9.99 | 195.88B | ||
PFE | PFIZER INC | 7.18 | 130.67B | ||
SNY | SANOFI-ADR | 13.71 | 128.55B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.41 | 95.71B | ||
GSK | GSK PLC-SPON ADR | 7.06 | 78.75B | ||
ZTS | ZOETIS INC | 26.91 | 72.25B | ||
HLN | HALEON PLC-ADR | 22.57 | 49.87B |
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The firm is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. The company is conducting Phase I/II study of NUV-1511.
NUVATION BIO INC
357 Tehama Street, Floor 3
San Francisco CALIFORNIA 94103 US
CEO: David Hung
Employees: 220
Phone: 14157543517
The current stock price of NUVB is 2.25 USD. The price increased by 10.84% in the last trading session.
The exchange symbol of NUVATION BIO INC is NUVB and it is listed on the New York Stock Exchange, Inc. exchange.
NUVB stock is listed on the New York Stock Exchange, Inc. exchange.
13 analysts have analysed NUVB and the average price target is 7.99 USD. This implies a price increase of 255.11% is expected in the next year compared to the current price of 2.25. Check the NUVATION BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NUVATION BIO INC (NUVB) has a market capitalization of 764.26M USD. This makes NUVB a Small Cap stock.
NUVATION BIO INC (NUVB) currently has 220 employees.
NUVATION BIO INC (NUVB) has a support level at 2.2 and a resistance level at 2.32. Check the full technical report for a detailed analysis of NUVB support and resistance levels.
The Revenue of NUVATION BIO INC (NUVB) is expected to grow by 594.71% in the next year. Check the estimates tab for more information on the NUVB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NUVB does not pay a dividend.
NUVATION BIO INC (NUVB) will report earnings on 2025-08-04, after the market close.
NUVATION BIO INC (NUVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
The outstanding short interest for NUVATION BIO INC (NUVB) is 13.37% of its float. Check the ownership tab for more information on the NUVB short interest.
ChartMill assigns a technical rating of 4 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is a bad performer in the overall market: 73.98% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NUVB. While NUVB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -96.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -123.13% | ||
ROE | -144.56% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 85% to NUVB. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -30.95% and a revenue growth 594.71% for NUVB